A Phase 2a Multicenter Randomized Double blind Study Evaluating the Efficacy and Safety of Subcutaneously Administered combination therapy in Improving the Signs and Symptoms in Participants with Active Psoriatic Arthritis.

Brief description of study

The purpose of this study is to see if guselkumab and golimumab, when used together, are safe and effective for treating participants with active Psoriatic Arthritis. Guselkumab (sold as TREMFYA®) has been approved for the treatment of moderate to severe psoriasis and active psoriatic arthritis. Golimumab (sold as SIMPONI®) has been approved for the treatment of rheumatoid arthritis, psoriatic arthritis, non-radiographic axial spondylarthritis, and ankylosing spondylitis. Though these drugs have been Food and Drug Administration (FDA) approved, for the purposes of this study they are considered "investigational", or experimental. This is because their use together as a combination therapy is being studied as a new treatment option.

Clinical Study Identifier: s21-00936
ClinicalTrials.gov Identifier: NCT05071664
Principal Investigator: Jose U Scher.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.